Fig. 8From: Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutationSchematic illustration of CML-RAE-1γ-Dex-based cancer immunotherapy. CML-RAE-1γ-Dex augment NK-cell and CD4+ and CD8+ T-cell activation in an NKG2D-dependent manner and amplify the immune response by promoting NK/T-cell proliferation. Created with BioRender.comBack to article page